SCHEMBL23590082

SCHEMBL23590082

CCOc1cccc(-c2ccc(-c3cc(C(=O)O)c4cc(F)ccc4n3)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 10/20 0.69
▸ KDM4E B2RXH2 4/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ HPGD P15428 2/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ RAB9A P51151 1/20 0.61
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ HSD17B10 Q99714 4/20 0.58
▸ GAA P10253 1/20 0.57
▸ PLA2G2A P14555 1/20 0.56
▸ RXRA P19793 1/20 0.54
▸ RXRB P28702 1/20 0.54
▸ CYP1A2 P05177 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590210 0.91 DHODH (0.58) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23576326 0.91 DHODH (0.70) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29918673 0.91 DHODH (0.70) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23576327 0.90 DHODH (0.71) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29617652 0.90 DHODH (0.71) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29996606 0.90 DHODH (0.57) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23579972 0.90 DHODH (0.57) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL25118724 0.90 DHODH (0.59) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23579626 0.89 DHODH (0.59) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29997396 0.89 DHODH (0.59) DHODHKDM4EALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4438042-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE Ohio State Innovation Foundation (US) 2024-10-02 — — EP disclosed
US-20240294477-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-09-05 — — US disclosed
EP-3793562-B1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-06-19 — — EP disclosed
US-11999697-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2024-06-04 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
WO-2023278778-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-01-05 — — WO disclosed
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2022-04-26 — — US disclosed
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2022-04-26 — — US disclosed
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE HENDRIX COLLEGE 2022-03-03 — — US disclosed
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION 2021-08-19 — — US disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD DHODH 1/4885KDM4E 474/4885ALDH1A1 72/4885
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885KDM4E 1396/4885ALDH1A1 88/4885
US-20240294477-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885KDM4E 523/4885ALDH1A1 64/4885
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885KDM4E 523/4885ALDH1A1 64/4885
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885KDM4E 474/4885ALDH1A1 72/4885
US-11999697-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD DHODH 1/4885KDM4E 523/4885ALDH1A1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback